Results 21 to 30 of about 2,084 (218)

Safety of a feed additive consisting of diclazuril (Clinacox® 0.5%) for chickens for fattening and chickens reared for laying (Elanco GmbH) [PDF]

open access: yesEFSA Journal
Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety of the coccidiostat diclazuril (Clinacox® 0.5%) for chickens for fattening and chickens reared for laying.
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)   +21 more
doaj   +2 more sources

Safety and efficacy of Coxiril® (diclazuril) for chickens reared for laying

open access: yesEFSA Journal, 2018
Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Coxiril® (diclazuril) for chickens reared for laying.
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)   +26 more
doaj   +3 more sources

Anticoccidial and immunogenic effectivity of encapsulated organic acids and anticoccidial drugs in broilers infected with Eimeria spp. [PDF]

open access: yesScientific Reports, 2022
The study was conducted to consider the anticoccidial and immunogenic effectivities of encapsulated organic acids and anticoccidial drugs in broilers reared on a reused litter infected with Eimeria spp.
Ali Nouri
doaj   +2 more sources

Combined transcriptome and whole genome sequencing analyses reveal candidate drug-resistance genes of Eimeria tenella [PDF]

open access: yesiScience
Summary: Avian coccidiosis is a widespread intestinal disease found in poultry that causes substantial economic losses. To extensively investigate the molecular mechanism of drug resistance in Eimeria tenella, we analyzed the sporozoites and second ...
Yu Yu   +7 more
doaj   +2 more sources

BIOCHEMICAL AND CHEMICAL PARAMETERS CHANGES IN THE BLOOD OF CHICKENS FOLLOWING TREATMENTS WITH MADURAMYCIN, MONENSIN AND DICLAZURIL [PDF]

open access: yesSlovenian Veterinary Research, 2017
The aim of this study was to monitor the biochemical and chemical parameters of the blood of commercial chickens following treatment with one of three coccidiostats: maduramycin, monensin or diclazuril. Chickens received feed treated with maduramycin at
Ines Varga   +8 more
doaj   +3 more sources

Toxoplasmosis Complications and Novel Therapeutic Synergism Combination of Diclazuril plus Atovaquone [PDF]

open access: yesFrontiers in Microbiology, 2014
Toxoplasmosis is a major cause of foodborne disease, congenital complication and morbidity. There is an urgent need for safe and effective therapies to encounter congenital and persisting toxoplasmosis.
Helieh S Oz
doaj   +3 more sources

Diclazuril Protects against Maternal Gastrointestinal Syndrome and Congenital Toxoplasmosis [PDF]

open access: yesInternational Journal of Clinical Medicine, 2014
BACKGROUND: Toxoplasmosis is a common cause of foodborne, gastrointestinal and congenital syndrome with particularly severe or unknown health consequences. There is no safe and effective preventive or therapeutic modality against congenital toxoplasmosis
Oz, Helieh S., Tobin, Thomas
core   +6 more sources

Modification of the conditions of the authorisation of BioPlus® 2B (Bacillus licheniformis DSM 5749 and Bacillus subtilis DSM 5750) for turkeys for fattening [PDF]

open access: yesEFSA Journal, 2019
Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the modification of the terms of the authorisation of BioPlus® 2B (Bacillus ...
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)   +24 more
doaj   +2 more sources

Novel Synergistic Protective Efficacy of Atovaquone and Diclazuril on Fetal-Maternal Toxoplasmosis [PDF]

open access: diamond, 2014
Over 1 billion people globally are estimated to be infected with Toxoplasma gondii with severe or unknown consequences and no safe and effective therapies are available against congenital or persistent chronic infection.
Oz, Helieh S.
core   +4 more sources

Home - About - Disclaimer - Privacy